AstraZeneca renews Tempus AI oncology deal with $200 million commitment

4 min read

AstraZeneca has committed $200 million in fees to Tempus AI over five years, under an oncology renewal the two signed on 16 November 2026, Tempus AI’s SEC filing shows. So it’s signed, but the new spending period doesn’t actually start until 1 January 2027, when the amendment kicks in, and from there it runs through 31 December 2031.

What exactly does AstraZeneca commit to?

A spending floor, not a payment up front: $200 million in fees over the Renewal Term, an annual target of $40 million, and at least $32 million in each calendar year. The 8-K says that spend runs across Tempus AI’s “existing and future products and services”.

The amendment itself holds the conditions. If the $200 million is not reached by the end of 2031, the term rolls over one year, to 31 December 2032. AstraZeneca keeps the right to end the agreement “for convenience at any time”, but then owes the shortfall: the unfulfilled part of the $200 million, plus whatever remains of the $220 million committed for the first term, which ends on 31 December 2026. The amendment also replaces the data licence and Lens terms of the Fourth Amendment of 14 March 2025, and some passages are left out as confidential, marked with asterisks.

OncoDaily reported the renewal on 19 November, quoting Tempus AI founder and CEO Eric Lefkofsky: “We’re proud to extend this strategic collaboration for another five years”. The master agreement behind it dates from 17 November 2021.

What does Ins7ghts’ record of AstraZeneca show?

Ins7ghts’ record shows AstraZeneca at three different deal steps in the same November weeks, and a Tempus AI delivery dated two ways. Ins7ghts, our research platform, counted 205 articles naming AstraZeneca between 13 July and 20 November 2026, busiest in the weeks of 3 to 9 August and 28 September to 4 October, at 18 each.

The delivery first. A KraneShares note of 5 November in the record has Tempus AI delivering its first AI model for cancer research to AstraZeneca. OncoDaily dates that delivery to July 2026. One event, two dates: the article’s and the step’s.

Then the deal ladder. Ins7ghts’ record has AstraZeneca at three steps within the same November weeks:

Date in the record Deal Step Source
8 Nov Rhythm Pharmaceuticals, $10 billion proposed, “still non-binding” Chosun Ilbo
9 Nov CSPC collaboration, $1.2 billion upfront, up to $3.5 billion in milestones announced Beroe paper, Clinical Leader
16 Nov Tempus AI renewal, $200 million in fees agreed, effective 1 January 2027 Tempus AI 8-K

Only the Tempus AI renewal rests on a signed, filed document in these sources. The Rhythm price is Chosun Ilbo’s report of a non-binding proposal.

Get the AI & data signal, daily.

41k+ read Ins7ghts, 25k+ read AI Beat. Ins7ghts and AI Beat: two free emails every morning on AI and data. Unsubscribe anytime.

What does it mean if you buy oncology data or AI?

For a buyer, it means weighing lock-in before signing a long commitment. The renewal ties $200 million of AstraZeneca’s spend to one supplier through 2031, and that supplier already serves other big drugmakers. The Beroe sourcing paper, published on Clinical Leader and Outsourced Pharma, counts Tempus among the providers that “each work with three” big pharma companies, and warns: “This concentration of demand into a limited number of platforms creates concentration and lock-in risks for buyers.”

For anyone weighing Tempus AI, the filing shows what a large customer’s terms look like: a yearly minimum, and an exit that still pays the balance. No price for the confidential parts of the exhibits appears in these sources.

What to watch: 1 January 2027, when the Renewal Term starts, and whether EU Standard Contractual Clauses are added after that date, which the amendment allows at AstraZeneca’s request.

AstraZeneca’s full record in Ins7ghts holds every dated event with the article it came from: ins7ghts.com.

Small print. The counts describe the news Ins7ghts collected from 13 July to 20 November 2026, not all news about AstraZeneca. Two articles in the record were not linked because their pages refuse readers today: a PitchBook News summary on teahose.com and Becaris Publishing’s October 2026 industry tracker. Dates in the table are the articles’ dates in the record; the deal dates come from the filing. AI models read the articles, wrote this take and checked every quote against its source on 20 November. I see each take the evening before it goes out.

Yves Mulkers

Yves Mulkers is the founder of 7wData and a widely followed voice in the data and AI community. He curates the 7wData and AI Beat newsletters, reaching hundreds of thousands of data and AI professionals, and writes on data strategy, analytics, AI, and the evolving data ecosystem.